Johnson & Johnson (JNJ.US) plans to spend $3.4 billion to acquire Ollin, doubling down on the retinal disease treatment track.
Zhitong Finance APP has learned that, according to people familiar with the matter, Johnson & Johnson (JNJ.US) may announce a deal as early as Monday to acquire Texas-based biotechnology company Ollin Biosciences for up to $3.4 billion. The report said that under the terms currently under discussion, Johnson & Johnson may pay Ollin's investors $2.2 billion in cash as an upfront payment, and may also pay up to $1.2 billion in milestone payments. However, the negotiations may still fall through, and the transaction has not yet been officially confirmed by both parties.
Latest

